photo taken from Nitin Jain/Twitter
Aug 31, 2023, 18:52
Nitin Jain: Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL.
Quoting Nitin Jain, the Director of Leukemia CAR-T Program at the MD Anderson Cancer Center:
“Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL, a high-risk disease subgroup. Development led by ORBIT Platform at MDACC MD Anderson Cancer Center. Marina Konopleva, Jeff Molldrem.“
For the article click here.
Source: Nitin Jain/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19